Back to Search
Start Over
Autologous HSCT for Multiple Sclerosis Should be Done Early in the Course of the Disease
- Source :
- Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p3593-3593, 1p
- Publication Year :
- 2023
-
Abstract
- Introduction:Multiple sclerosis (MS) is a disabling disease that affects young adults. Treatments for MS have increased exponentially in number, efficacy and risk. Autologous hematopoietic stem cell transplantation (aHSCT) can change the natural history of the disease. To analyze if aHSCT should be done early in the course of the disease or after failing of other therapies, we have studied the long-term results of aHSCT in a cohort of persons with MS
Details
- Language :
- English
- ISSN :
- 00064971 and 15280020
- Volume :
- 142
- Issue :
- 1, Number 1 Supplement 1
- Database :
- Supplemental Index
- Journal :
- Blood
- Publication Type :
- Periodical
- Accession number :
- ejs64705047
- Full Text :
- https://doi.org/10.1182/blood-2023-181433